CJ CheilJedang announced its clinical efficacy for children with atopic dermatitis when taking Kimchi Lactobacillus CJLP133 at the 2017 EAACI Congress held in Helsinki, Finland.
- CJ CheilJedang Announced the Effects of Kimchi Lactobacillus CJLP133 at the Largest Event in the Field of Allergies
▲ Kimchi lactic acid bacterium announced atopy improvement effects
The EAACI Congress is an annual conference organized by the European Association of Allergy and Clinical Immunology (EAACI), the largest nonprofit medical association in Europe in the fields of allergy and clinical immunology. Since 1956, experts have exchanged information about new studies and discoveries at this authoritative academic conference. Currently, the EAACI has more than 9,000 members in 121 countries and 50 national societies.
Professor Kim Ji-Hyun, a co-researcher in a Kimchi lactobacillus clinical trial, made a presentation on “the effects of CJLP133, a kimchi-derived skin-friendly lactobacillus, on atopic dermatitis” during the conference. There are two main points of research contents. First, the research proved once again that skin-friendly lactobacillus could help improve skin conditions caused by immune hypersensitivity.. Second, skin lactic acid bacteria had a greater effect on people who suffered from increased allergic inflammation due to food, dust mites, and so on among those with atopic dermatitis.
- Atopic Subjects Showed a Drop in Skin Itchiness Index After Taking Kimchi Lactic Acid Bacteria for 12 Weeks
▲ CJ CheilJedang’s BYO Skin Lactobacillus CJLP133
Researchers had 76 children and teenagers with atopic dermatitis aged between 2 to 18 years old take one bag (2g) of lactic acid bacteria every day for 12 weeks. The SCORAD (SCORing Atopic Dermatitis) points of the subjects sank from 31.6 to 24.0. Among them, patients with allergies to eggs, milk, soybeans, wheat, peanuts, and other foods saw their SCORAD points drop from 34.3 to 24.8. Those of people with allergic reactions to dust mites fell to 23.8 from 32.5. The SCORAD points are an index that expresses the degree of the deepening of skin symptoms. If an SCORAD score is less than 25 points, the symptom is deemed to be weak.
"There is growing social interest in food allergy prevention and treatment such as the Ministry of Food and Drug Safety’s introduction of allergy-inducing food labeling," said Kim Bong-Joon, a developer of kimchi lactic acid bacteria and the director of the Useful Microbe Center CJ CheilJedang. “Therefore, the results of the study which showed that kimchi lactic acid bacteria had a greater positive impact on atopy patients with food and dust mite allergies are more meaningful. We will actively promote the benefits of Korean kimchi lactic acid bacteria in foreign countries to help improve the health of people around the world by focusing more on studying the efficacy of CJLP133 skin lactic acid bacteria."
CJ CheilJedang started a full-fledged kimchi lactic acid bacterium research project in 2007, and released BYO Skin Lactobacillus CJLP133 in December 2013. This product with Lactobacillus Plantarum CJLP133, was found to be effective against skin itchiness and was recognized for the first time by the Ministry of Food and Drug Safety for an improvement in skin conditions stemming from immune hypersensitivity.